Trials Now Enrolling
There are several ongoing clinical trials at KCUMB. To learn more about participating, visit our
Volunteer Education Center. If you do not see a study below that interests you, you may still sign up for future studies.
- Learn more about our Refer-a-Friend program: Refer a qualified participant and you could earn up to $200!
Select a category or scroll down to see all studies now enrolling:
| AIDS/HIV Asthma Allergies, Seasonal Cholesterol Chronic Back Pain Chronic Bronchitis COPD |
Diabetes Emphysema Fibromyalgia Gastro-esophageal Reflux High Cholesterol Hypertension |
Infectious Disease Influenza Irritable Bowel Syndrome Pregnancy Reactive Airway Disorder |
Title: Merck MK0653C in High Heart/Blood Vessel Risk Individuals With High Cholesterol
Description: We are conducting a research study to compare the effectiveness and safety of taking ezetimibe (Zetia) and atorvastatin (Lipitor) together compared to taking atorvastatin (Lipitor) or rosuvastatin (Crestor) alone. For more information, visit the study's pages at clinicaltrials.gov
Duration: 8 outpatient visits
Compensation: Investigational cholesterol lowering medication and study-related care at no cost, as well as compensation for time. Reimbursement for childcare and transportation may be provided.
Eligibility requirements: 18 to 80 years, diagnosed with high cholesterol, taking a stable dose of cholesterol lowering medication for at least 6 months or not taking medication for high cholesterol for at least 6 months.
Contact Information: Dybedal Clinical Research Center, crc@kcumb.edu or 1-877-425-0250.
Title: ViiV/GSK ASSURE EPZ113734 – A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine Without Ritonavir for 48 weeks in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Description: We are conducting a research study to Compare the efficacy and safety of simplifying from a regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine without Ritonavir. For more information, visit the study's pages at clinicaltrials.gov
Duration: 9 outpatient visits
Compensation: Investigational medication and study-related care at no cost, as well as compensation for time. Reimbursement for childcare and transportation may be provided.
Eligibility requirements: must be 18 years of age or older, diagnosed with HIV-1, taking a stable antiretroviral regimen of Reyataz 300 mg / Norvir 100 mg + Viread 300 mg / 200 mg for at least 6 months, no prior exposure to Abacavir-containing regimens and must have a detectable viral load.
Contact Information: Dybedal Clinical Research Center, crc@kcumb.edu or 1-877-425-0250.
Category: HIV
Title: ViiV/GSK SAILING ING111762 – A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK134972 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily. Both Administered with an Investigator-selected Background Regimen Over 48 weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults.
Description: We are conducting a research study to study the safety and efficacy of GSK134972 50 mg once daily versus Raltegravir 400 mg twice daily. For more information, visit the study's pages at clinicaltrials.gov
Duration: 13 outpatient visits
Compensation: Investigational HIV medication (GSK134972 & Raltegravir) and study-related care at no cost, as well as compensation for time. Reimbursement for childcare and transportation may be provided.
Eligibility requirements: must be 18 years of age or older, diagnosed with HIV-1, taking a stable dose of antiretroviral regimen for at least 6 months, no prior exposure to Isentress (raltegravir, or RAL) or Elvitegravir and must have an undetectable viral load.
Contact Information: Dybedal Clinical Research Center, crc@kcumb.edu or 1-877-425-0250.